Literature DB >> 17882279

Acute-myeloid-leukemia-targeted toxins kill tumor cells by cell-type-specific mechanisms and synergize with TRAIL to allow manipulation of the extent and mechanism of tumor cell death.

H Horita, A E Frankel, A Thorburn.   

Abstract

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17882279     DOI: 10.1038/sj.leu.2404956

Source DB:  PubMed          Journal:  Leukemia        ISSN: 0887-6924            Impact factor:   11.528


× No keyword cloud information.
  5 in total

1.  Activity of SL-401, a targeted therapy directed to interleukin-3 receptor, in blastic plasmacytoid dendritic cell neoplasm patients.

Authors:  Arthur E Frankel; Jung H Woo; Chul Ahn; Naveen Pemmaraju; Bruno C Medeiros; Hetty E Carraway; Olga Frankfurt; Stephen J Forman; Xuezhong A Yang; Marina Konopleva; Francine Garnache-Ottou; Fanny Angelot-Delettre; Christopher Brooks; Michael Szarek; Eric Rowinsky
Journal:  Blood       Date:  2014-05-23       Impact factor: 22.113

2.  EGFR-targeted diphtheria toxin stimulates TRAIL killing of glioblastoma cells by depleting anti-apoptotic proteins.

Authors:  Henrick Horita; Jacqueline Thorburn; Arthur E Frankel; Andrew Thorburn
Journal:  J Neurooncol       Date:  2009-05-17       Impact factor: 4.130

3.  Regulation of HMGB1 release by autophagy.

Authors:  Jacqueline Thorburn; Arthur E Frankel; Andrew Thorburn
Journal:  Autophagy       Date:  2009-02-05       Impact factor: 16.016

Review 4.  TRAIL receptor-targeted therapeutics: resistance mechanisms and strategies to avoid them.

Authors:  Andrew Thorburn; Kian Behbakht; Heide Ford
Journal:  Drug Resist Updat       Date:  2008-04-18       Impact factor: 18.500

5.  Acute myeloid leukemia-targeted toxin activates both apoptotic and necroptotic death mechanisms.

Authors:  Henrick Horita; Arthur E Frankel; Andrew Thorburn
Journal:  PLoS One       Date:  2008-12-11       Impact factor: 3.240

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.